期刊
CANCER DISCOVERY
卷 8, 期 11, 页码 1352-1354出版社
AMER ASSOC CANCER RESEARCH
DOI: 10.1158/2159-8290.CD-18-1084
关键词
-
类别
资金
- Breast Cancer Research Foundation [BCRF-17-143]
- NCI [K08 CA191058-02]
The correlative circulating tumor DNA (ctDNA) studies of the PALOMA-3 clinical trial showed that acquired resistance to fulvestrant and palbociclib is associated with clonal evolution and acquired mutations in RB1, PIK3CA, and ESR1, with the latter two related to fulvestrant resistance. These results highlight the potential of ctDNA as a tool to detect mechanisms of resistance and infer the next line of treatment. (C) 2018 AACR.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据